Neratinib in Early-Stage HER2-Positive Breast Cancer

被引：1
|
作者：
Cherian, Mathew A.
Ma, Cynthia X.
机构：
来源：
BREAST DISEASES | 2015年 / 26卷 / 04期
关键词：
D O I：
10.1016/j.breastdis.2015.10.040
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
[No abstract available]
引用
收藏
页码：285 / 287
页数：4
相关论文
共 50 条
  • [1] Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
    Kourie, Hampig Raphael
    El Rassy, Elie
    Clatot, Florian
    de Azambuja, Evandro
    Lambertini, Matteo
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 3363 - 3372
  • [2] Neratinib for the treatment of HER2-positive early stage breast cancer
    Echavarria, Isabel
    Lopez-Tarruella, Sara
    Marquez-Rodas, Ivan
    Jerez, Yolanda
    Martin, Miguel
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (08) : 669 - 679
  • [3] Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
    Barcenas, C. H.
    Hurvitz, S. A.
    Di Palma, J. A.
    Bose, R.
    Chien, A. J.
    Iannotti, N.
    Marx, G.
    Brufsky, A.
    Litvak, A.
    Ibrahim, E.
    Alvarez, R. H.
    Ruiz-Borrego, M.
    Chan, N.
    Manalo, Y.
    Kellum, A.
    Trudeau, M.
    Thirlwell, M.
    Saenz, J. Garcia
    Hunt, D.
    Bryce, R.
    McCulloch, L.
    Rugo, H. S.
    Tripathy, D.
    Chan, A.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (09) : 1223 - 1230
  • [4] Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
    Schwartz, Naomi R. M.
    Flanagan, Meghan Rose
    Babigumira, Joseph B.
    Steuten, Lotte Maria Gertruda
    Roth, Joshua A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Advances in the Treatment of Early-Stage HER2-Positive Breast Cancer
    Sharifi, Marina
    Wisinski, Kari B.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (08) : 482 - 492
  • [6] Systemic therapy for HER2-positive early-stage breast cancer
    Mathew, Aju
    Romond, Edward H.
    [J]. CURRENT PROBLEMS IN CANCER, 2016, 40 (2-4) : 106 - 116
  • [7] Risk of Recurrence in Early-Stage, HER2-Positive Breast Cancer
    Isaacs, Claudine
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (08) : 3 - 6
  • [8] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Tran, Phuong T.
    Diaby, Vakaramoko
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 221 - 221
  • [9] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [10] Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive, HER2-positive early-stage breast cancer
    Blanter, Julia
    Baldwin, Elena
    Patel, Rima
    Sheng, Tianxiang
    Tiersten, Amy
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2024,
12345